Cancer Research Technology, the commercial arm of Cancer Research UK has spun off a private comapny called ‘Acublate Limited’ which will be developing a HIFU device used to treat various types of solid tumors. Initially, the Acublate device will treat patients with bowel cancer that has spread to the liver.
Dr Keith Blundy, CRT’s CEO, said: “We’re delighted to be able to take the research into this exciting technology that Cancer Research UK helped fund onto the next stage. The HIFU technology currently approved for clinical use in the UK specifically targets prostate cancer but we hope the Acublate device will be able to treat most solid tumour types.”
Read the press release here: